Working… Menu

Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents (OPTIMA-C)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03056118
Recruitment Status : Completed
First Posted : February 17, 2017
Last Update Posted : February 17, 2017
Information provided by (Responsible Party):
Hyuck moon Kwon, Gangnam Severance Hospital

Brief Summary:
Investigators try to assess the safety of 6-months or 12-months maintenance of dual antiplatelet therapy (DAPT, aspirin + clopidogrel) in patients undergoing percutaneous coronary intervention using the Zotarolimus-eluting, Resolute Integrity™ stent (Medtronic Vascular Inc, Santa Rosa, CA) or the BioMatrix™ stent (Biosensors. Singapore).

Condition or disease Intervention/treatment Phase
Ischemic Heart Disease Drug: 6-month dual anti-platelet therapy Drug: 12-month dual anti-platelet therapy Device: Zotarolimus eluting stent Device: Biolimus eluting stent Phase 4

Detailed Description:

Dual antiplatelet therapy (DAPT) has proven the most effective treatment in reducing thrombotic complications after drug eluting stent (DES) implantation. Although the optimal duration of antiplatelet therapy is still under investigation, late stent thrombosis (ST) with DES has pushed the recommendation for duration of clopidogrel therapy for one year or more, in patients without risks for bleeding. However, recent controversies regarding the risk of stent thrombosis in patients receiving DES has brought up the issue of the appropriate duration of antiplatelet therapy after percutaneous coronary intervention, and a recent study reported that the use of extended DAPT for a period longer than 12 months in patients who had received DES was not significantly more effective than aspirin monotherapy in reducing the rate of myocardial infarction (MI) or death for cardiac causes.

Zotarolimus-eluting stent (Resolute Integrity™) and biolimus-eluting stent with biodegradable polymer system (BioMatrix™) share several similarities. Both stents are flexible thin strut stents eluting sirolimus-analogue drugs targeting at mammalian target of rapamycin. The advantages that Resolute Integrity™ stent strut is quite thin and coated with highly biocompatible polymer and BioMatrix™ stent has the abluminal drug coating system with biodegradable polymer might provide clinical studies showing that both stents are quite safe as well as efficacious. Moreover, recent report showed that continuation of clopidogrel for only 3 months after implantation of Endeavor stent seems to be safe in low-to-moderate coronary artery risk group. Based on these clinical evidences, the duration of DAPT continuation for 12 months or less after implantation of Resolute Integrity™ or BioMatrix™ stent, 'the second generation DES', would be safe, however, there are no data available about this. Therefore, the purpose of this study is to assess the safety of 6-months or 12-months maintenance of DAPT in patients undergoing percutaneous coronary intervention (PCI) using Resolute Integrity™ or BioMatrix™ stent.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1368 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Optimal Duration of Clopidogrel After Implantation of Second-Generation Drug-Eluting Stents (OPTIMA-C)
Actual Study Start Date : May 2, 2011
Actual Primary Completion Date : June 1, 2015
Actual Study Completion Date : September 7, 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 6-month dual anti-platelet therapy
maintain dual anti-platelet agents for 6 months
Drug: 6-month dual anti-platelet therapy
Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 6 months
Other Name: Aspirin and Clopidogrel

Active Comparator: 12-month dual anti-platelet therapy
maintain dual anti-platelet agents for 12 months
Drug: 12-month dual anti-platelet therapy
Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 12 months
Other Name: Aspirin and Clopidogrel

Active Comparator: Zotarolimus eluting stent arm
implant with zotarolimus eluting stent (Resolute Integrity)
Device: Zotarolimus eluting stent
Zotarolimus eluting stent is applied to coronary stenotic lesion

Active Comparator: Biolimus eluting stent arm
implant with biolimus eluting stent (Biomatrix)
Device: Biolimus eluting stent
Biolimus eluting stent is applied to coronary stenotic lesion

Primary Outcome Measures :
  1. A composite of major adverse cardiac events (MACE; cardiac death, target vessel MI and ischemia driven-target lesion revascularization; TLR) [ Time Frame: 12 months ]
    1. Cardiac death: Any death due to proximate cardiac cause (eg, MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, and all procedure-related deaths, including those related to concomitant treatment, will be classified as cardiac death.
    2. MI Classification and Criteria for Diagnosis is defined by the Academic Research Consortium
    3. TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLRs should be classified prospectively as clinically indicated* or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject must be at least 20 years of age.
  2. Subject must have evidence of myocardial ischemia (e.g. stable angina, non-ST elevation acute coronary syndrome, silent ischemia, positive functional study or a reversible changes in the electrocardiogram (ECG) consistent with ischemia).
  3. Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving the Resolute Integrity or BioMatrix stent and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.

Exclusion Criteria:

  1. Acute ST elevation myocardial infarction
  2. The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, zotarolimus, biolimus, contrast media
  3. Clinical conditions requiring systemic immune suppression over 2 weeks or anti-cancer therapy
  4. Prior history of the following presentations: Thromboembolic disease, Stent thrombosis
  5. Pregnant women or women with childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
  6. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions.
  7. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
  8. Current known current platelet count < 100,000 cells/mm3 or Hgb <10 g/dL.
  9. Non-cardiac co-morbid conditions are present with life expectancy < 1 year or that may result in protocol non-compliance (per site investigator's medical judgment
  10. Patients with left ventricular ejection fraction < 35%
  11. Patients with cardiogenic shock
  12. Creatinine level > 2.4mg/dL
  13. Severe hepatic dysfunction (aspartate aminotransferase and/or alanine aminotransferase ≥ 3 times upper normal reference values)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03056118

Sponsors and Collaborators
Gangnam Severance Hospital
Layout table for investigator information
Principal Investigator: Hyuck moon Kwon Gangnam Severance Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Hyuck moon Kwon, Professor, Gangnam Severance Hospital Identifier: NCT03056118    
Other Study ID Numbers: 3-2011-0054
First Posted: February 17, 2017    Key Record Dates
Last Update Posted: February 17, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: If PI and scientific committee approve to share individual participant data to other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hyuck moon Kwon, Gangnam Severance Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Myocardial Ischemia
Coronary Artery Disease
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arterial Occlusive Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents